HRP20240793T1 - Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba - Google Patents
Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba Download PDFInfo
- Publication number
- HRP20240793T1 HRP20240793T1 HRP20240793TT HRP20240793T HRP20240793T1 HR P20240793 T1 HRP20240793 T1 HR P20240793T1 HR P20240793T T HRP20240793T T HR P20240793TT HR P20240793 T HRP20240793 T HR P20240793T HR P20240793 T1 HRP20240793 T1 HR P20240793T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- alkyl
- compound according
- halo
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
Claims (15)
1. Spoj formule IV ili VI:
[image]
ili
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time što:
R1 je -SCH3 ili klor;
X je CH;
Ra je vodik, (C1-C4)alkil, ili halo(C1-C4)alkil;
Rb je (C1-C4)alkil, halo(C1-C4)alkil, ili 4-7 pri čemu je navedeni heterociklil izborno supstituiran s 1 do 3 skupine odabrane iz niza koji sadrži halo, (C1-C4)alkil, halo(C1-C4)alkil, (C1-C4)alkoksi, i halo(C1-C4)alkoksi; ili
Ra i Rb zajedno s atomom dušika na koji su oni vezani tvore 4-7 člani heterociklil po izboru supstituiran s 1 do 3 skupine odabrane iz niza koji sadrži halo, (C1-C4)alkil, halo(C1-C4)alkil, i -ORc;
Rc je (C1-C4)alkil, halo(C1-C4)alkil, ili (C3-C7)cikloalkil;
R6 je halo(C1-C4)alkil.
2. Spoj prema zahtjevu 1, naznačen time što spoj ima formulu:
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema bilo kojem od zahtjeva 1 ili 2, naznačen time što Rb je (C1-C4)alkil ili oksetanil, pri čemu je navedeni oksetanil izborno supstituiran s halo(C1-C4)alkilom; ili Ra i Rb zajedno s atomom dušika na koji su oni vezani tvore azetidinil izborno supstituiran s halo ili -ORc.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time što Ra je vodik ili metil; i Rb je metil ili oksetanil, pri čemu je navedeni oksetanil izborno supstituiran s -CH2F ili - CF3.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time što Ra i Rb zajedno s atomom dušika na koji su oni vezani tvore azetidinil izborno supstituiran s 1 do 2 fluora ili -ORc; i Rc je -CH3, -CHF2, ili ciklopropil.
6. Spoj prema zahtjevu 1, naznačen time što spoj ima formulu:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili
[image]
ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time što skupina
[image]
i NRaRb su orijentirani trans oko cikloheksila.
8. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time što skupina
[image]
i NRaRb su orijentirani cis oko cikloheksila.
9. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time što stereokemijska konfiguracija kiralnog središta 1,3-dioksolanila je R.
10. Spoj prema bilo kojem od zahtjeva 1 do 8, stereokemijska konfiguracija kiralnog središta 1,3-dioksolanila je S.
11. Spoj prema zahtjevu 1, naznačen time što spoj ima formulu:
[image]
ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema zahtjevu 11, naznačen time što spoj ima formulu:
[image]
ili njegova farmaceutski prihvatljiva sol.
13. Farmaceutski pripravak naznačen time što sadrži spoj prema bilo kojem od zahtjeva 1 do 12, ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač.
14. Spoj prema bilo kojem od zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, za upotrebu u liječenju raka kod subjekta.
15. Spoj za upotrebu prema zahtjevu 14, naznačen time što je rak odabran između raka dojke, raka prostate, raka debelog crijeva, karcinoma bubrežnih stanica, multiformnog glioblastoma, raka mokraćnog mjehura, melanoma, raka bronha, limfoma, kolangiosarkoma, multiplog mijeloma, raka pluća, raka jajnika, i raka jetre.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659408P | 2018-04-18 | 2018-04-18 | |
| EP19722363.9A EP3781561B1 (en) | 2018-04-18 | 2019-04-17 | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PCT/US2019/027932 WO2019204490A1 (en) | 2018-04-18 | 2019-04-17 | Modulators of methyl modifying enzymes, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240793T1 true HRP20240793T1 (hr) | 2024-09-13 |
Family
ID=66429588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240793TT HRP20240793T1 (hr) | 2018-04-18 | 2019-04-17 | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10689371B2 (hr) |
| EP (2) | EP3781561B1 (hr) |
| JP (2) | JP7256823B2 (hr) |
| KR (2) | KR102798145B1 (hr) |
| CN (2) | CN111989325B (hr) |
| AR (1) | AR114793A1 (hr) |
| AU (1) | AU2019255310B2 (hr) |
| BR (1) | BR112020021194A2 (hr) |
| CA (1) | CA3098428A1 (hr) |
| CL (1) | CL2020002698A1 (hr) |
| CO (1) | CO2020014217A2 (hr) |
| CR (1) | CR20200553A (hr) |
| DK (1) | DK3781561T3 (hr) |
| EA (1) | EA202092490A1 (hr) |
| ES (1) | ES2983344T3 (hr) |
| FI (1) | FI3781561T3 (hr) |
| HR (1) | HRP20240793T1 (hr) |
| HU (1) | HUE066783T2 (hr) |
| IL (1) | IL278013B2 (hr) |
| LT (1) | LT3781561T (hr) |
| MA (1) | MA52288B1 (hr) |
| MD (1) | MD3781561T2 (hr) |
| MX (1) | MX2020010999A (hr) |
| PE (1) | PE20201448A1 (hr) |
| PH (1) | PH12020551578A1 (hr) |
| PL (1) | PL3781561T3 (hr) |
| PT (1) | PT3781561T (hr) |
| RS (1) | RS65621B1 (hr) |
| SG (1) | SG11202009438UA (hr) |
| SI (1) | SI3781561T1 (hr) |
| SM (1) | SMT202400233T1 (hr) |
| TW (1) | TWI828677B (hr) |
| UA (1) | UA127357C2 (hr) |
| WO (1) | WO2019204490A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009438UA (en) | 2018-04-18 | 2020-11-27 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN120097995A (zh) | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| KR102689665B1 (ko) | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| KR20220041130A (ko) * | 2019-07-24 | 2022-03-31 | 콘스텔레이션 파마슈티칼스, 인크. | 암 치료를 위한 병용 요법에서의 ezh2 억제 |
| BR112022001161A2 (pt) * | 2019-07-24 | 2022-06-07 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
| TW202144341A (zh) * | 2020-03-13 | 2021-12-01 | 大陸商四川海思科製藥有限公司 | Zeste同源基因增強子2抑制劑及其用途 |
| CN113666920A (zh) * | 2020-04-14 | 2021-11-19 | 上海华汇拓医药科技有限公司 | 苯并恶唑类化合物制备方法及其在医药领域的应用 |
| IL299730A (en) * | 2020-07-08 | 2023-03-01 | Daiichi Sankyo Co Ltd | Method for producing 1,3-benzodioxole derivative |
| US20230414593A1 (en) * | 2020-11-18 | 2023-12-28 | Constellation Pharmaceuticals, Inc | Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers |
| KR20220101295A (ko) | 2021-01-11 | 2022-07-19 | 주식회사 엘지에너지솔루션 | 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법 |
| JP2025504821A (ja) * | 2022-01-14 | 2025-02-19 | トンファ ファーム カンパニー リミテッド | １，３－ベンゾジオキソール誘導体化合物およびそれを含む薬剤学的組成物 |
| CN116496263A (zh) * | 2022-01-27 | 2023-07-28 | 江苏天士力帝益药业有限公司 | Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用 |
| WO2023217018A1 (zh) * | 2022-05-07 | 2023-11-16 | 贝达药业股份有限公司 | Ezh2抑制剂及其在医药上的应用 |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| TW202415655A (zh) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑 |
| KR20250052388A (ko) | 2022-08-17 | 2025-04-18 | 인사이트 코포레이션 | 항-cd19 항체 및 ezh2 조절제를 포함하는 요법 |
| WO2025008783A1 (ko) * | 2023-07-06 | 2025-01-09 | 동화약품주식회사 | 1,3-벤조다이옥솔 유도체 화합물을 포함하는 약학적 조성물 |
| WO2025124531A1 (en) * | 2023-12-15 | 2025-06-19 | Gewu Bio Co., Ltd | 1, 3-benzodioxol derivatives and uses thereof |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6317850A (ja) | 1986-07-11 | 1988-01-25 | Fuji Photo Film Co Ltd | ３−フエノキシカテコ−ル類の製造方法 |
| IL92544A0 (en) | 1988-12-08 | 1990-08-31 | Duphar Int Res | Piperazine derivatives,their preparation and pharmaceutical compositions containing them |
| JPH02255674A (ja) | 1989-03-27 | 1990-10-16 | Fuji Photo Film Co Ltd | ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法 |
| JPH02255673A (ja) | 1989-03-27 | 1990-10-16 | Fuji Photo Film Co Ltd | ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法 |
| JPH02269352A (ja) | 1989-04-10 | 1990-11-02 | Fuji Photo Film Co Ltd | 感光材料 |
| JP2537682B2 (ja) | 1989-04-21 | 1996-09-25 | 富士写真フイルム株式会社 | ３―アリ―ルオキシカテコ―ル類の製造方法 |
| US5296497A (en) | 1989-05-16 | 1994-03-22 | Duphar International Research B.V. | 3,4-dehydropiperidine derivatives having psychotropic activity |
| JPH03130280A (ja) | 1989-10-17 | 1991-06-04 | Fuji Photo Film Co Ltd | ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法 |
| JP2816492B2 (ja) | 1990-05-23 | 1998-10-27 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
| JPH0446175A (ja) | 1990-06-14 | 1992-02-17 | Fuji Photo Film Co Ltd | ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法 |
| JPH0641038A (ja) | 1992-07-17 | 1994-02-15 | Mitsubishi Kasei Corp | カルボン酸誘導体 |
| DE4326151A1 (de) | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
| US5629200A (en) | 1993-11-18 | 1997-05-13 | Daicel Chemical Industries, Ltd. | Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| AU709113B2 (en) | 1996-01-29 | 1999-08-19 | Regents Of The University Of California, The | Method for treating sexual dysfunctions |
| US5968929A (en) | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| JPH10287654A (ja) | 1997-04-11 | 1998-10-27 | Nissan Chem Ind Ltd | ピラゾロン誘導体及び除草剤 |
| EP1026950B1 (en) | 1997-10-27 | 2006-02-08 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| CZ303899B6 (cs) | 1998-09-29 | 2013-06-19 | Wyeth Holdings Corporation | Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem |
| EP1384713B1 (en) * | 1998-12-23 | 2008-10-15 | SmithKline Beecham Corporation | 4-amino-azepan-3-one derivatives as protease inhibitors |
| US7977333B2 (en) | 2000-04-20 | 2011-07-12 | Bayer Healthcare Llc | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| KR20080027400A (ko) | 2000-08-21 | 2008-03-26 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| WO2002016327A1 (en) | 2000-08-23 | 2002-02-28 | The Procter & Gamble Company | Benzimidazoles and analogues and their use as neutrophil inhibitors |
| PT2264018E (pt) | 2000-08-24 | 2015-06-03 | Univ Pittsburgh | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer |
| AUPR255401A0 (en) | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
| WO2002074307A1 (en) | 2001-03-16 | 2002-09-26 | Novogen Research Pty Ltd | Treatment of restenosis |
| US6716840B2 (en) | 2001-04-09 | 2004-04-06 | Chiron Corporation | Guanidino compounds |
| ATE409185T1 (de) | 2001-04-19 | 2008-10-15 | Astrazeneca Ab | Chinazolin derivate |
| DE10148618B4 (de) | 2001-09-25 | 2007-05-03 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| DE10148617A1 (de) | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AUPR846401A0 (en) | 2001-10-25 | 2001-11-15 | Novogen Research Pty Ltd | 6-Hydroxy isoflavones, derivatives and medicaments involving same |
| EP1503986B1 (en) | 2001-12-21 | 2015-09-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| US7524883B2 (en) | 2002-01-08 | 2009-04-28 | Eisai R&D Management Co., Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US20060167083A1 (en) | 2002-04-09 | 2006-07-27 | Kelly Graham E | Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| DE10219294A1 (de) | 2002-04-25 | 2003-11-13 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| NZ537685A (en) | 2002-07-29 | 2007-06-29 | Hoffmann La Roche | Novel benzodioxoles |
| AU2002951271A0 (en) | 2002-09-06 | 2002-09-19 | Novogen Research Pty Ltd | Repair of dna mutagenic damage |
| US20060153782A1 (en) | 2002-09-23 | 2006-07-13 | Novogen Research Pty Ltd | Skin photoageing and actinic damage treatment |
| CA2531140C (en) | 2003-07-28 | 2013-06-18 | Applied Research Systems Ars Holding N.V. | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP1685140A4 (en) | 2003-11-18 | 2009-02-25 | Novogen Res Pty Ltd | PRODRUGS BASED ON ISOFLAVONOIDS, COMPOSITIONS THEREOF AND THERAPEUTIC PROCESSES INVOLVING THEM |
| NZ546150A (en) | 2003-11-19 | 2010-04-30 | Novogen Res Pty Ltd | Radiosensitization using isoflavones |
| US7432377B2 (en) | 2004-01-16 | 2008-10-07 | Wyeth | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof |
| AU2005233125A1 (en) | 2004-04-07 | 2005-10-27 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US20050245529A1 (en) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| CA2565200C (en) | 2004-05-07 | 2013-12-24 | Exelixis, Inc. | Raf modulators and methods of use |
| EP1753428A4 (en) | 2004-05-14 | 2010-09-15 | Abbott Lab | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS |
| ITMI20041347A1 (it) | 2004-07-05 | 2004-10-05 | Italfarmaco Spa | Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| US20090042773A1 (en) | 2004-10-12 | 2009-02-12 | Reinhard Wetzker | P13 kinase gamma inhibitors for the treatment of anaemia |
| SE0402635D0 (sv) | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
| JP2006145294A (ja) | 2004-11-17 | 2006-06-08 | Univ Nagoya | 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法 |
| US7524870B2 (en) | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
| DK1859793T3 (da) | 2005-02-28 | 2011-08-01 | Eisai R&D Man Co Ltd | Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer |
| WO2006096807A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| US20080194552A1 (en) | 2005-03-31 | 2008-08-14 | Astrazeneca Ab | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity |
| KR20070120182A (ko) | 2005-04-08 | 2007-12-21 | 바이엘 파마슈티칼스 코포레이션 | 피리미딘 유도체 및 암의 치료에서의 이의 용도 |
| PL1881823T3 (pl) | 2005-05-17 | 2015-05-29 | Sarcode Bioscience Inc | Kompozycje i sposoby leczenia chorób oczu |
| JP2008542267A (ja) | 2005-05-25 | 2008-11-27 | ワイス | ３−シアノ−キノリンと、それにより製造される中間体とを調製する方法 |
| JPWO2006129609A1 (ja) | 2005-05-30 | 2009-01-08 | 塩野義製薬株式会社 | ２−ナフチルイミノ−５，５−ジ置換−１，３−チアジン誘導体 |
| AU2006252768A1 (en) | 2005-06-02 | 2006-12-07 | Bayer Cropscience Ag | Phenylalkyl substituted heteroaryl devivatives |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| CN101495184A (zh) | 2005-07-15 | 2009-07-29 | Amr科技公司 | 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用 |
| JP2009502809A (ja) | 2005-07-21 | 2009-01-29 | パラテック ファーマシューティカルズ インコーポレイテッド | １０−置換テトラサイクリンおよびその使用方法 |
| NZ565334A (en) | 2005-08-04 | 2010-12-24 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| WO2007020936A1 (ja) | 2005-08-17 | 2007-02-22 | Daiichi Sankyo Company, Limited | 抗真菌作用二環性複素環化合物 |
| WO2007081630A2 (en) | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
| CN101007798B (zh) | 2006-01-24 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途 |
| DK1996180T3 (da) | 2006-03-23 | 2011-10-31 | Biota Scient Management | Benzamid- og pyridylamidderivater som antibakterielle midler |
| DE602007006486D1 (de) | 2006-05-30 | 2010-06-24 | Neurosearch As | Neuartige 1,4-diaza-bicycloä3.2.2ünonyl-oxadiazolyl-derivate und ihre medizinische verwendung |
| US20100035877A1 (en) | 2006-06-26 | 2010-02-11 | Katz David M | Methods and compositions for treating pathologies associated with bdnf signaling |
| WO2008029168A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| AU2007314141A1 (en) | 2006-10-30 | 2008-05-08 | Novogen Research Pty Ltd | Prevention and reversal of chemotherapy-induced peripheral neuropathy |
| RU2333211C1 (ru) | 2006-11-01 | 2008-09-10 | Институт физиологически активных веществ Российской Академии наук | N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения |
| AU2008251557B2 (en) | 2007-05-10 | 2012-12-06 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| BRPI0704074B8 (pt) | 2007-08-29 | 2021-05-25 | Univ Estadual Paulista Julio De Mesquita Filho Unesp | derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação |
| ES2830024T3 (es) | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| CN102066339B (zh) | 2008-04-16 | 2014-09-24 | 波托拉医药品公司 | 作为syk或jak蛋白激酶抑制剂的2，6-二氨基-嘧啶-5-基甲酰胺类化合物 |
| CN102131777B (zh) | 2008-06-23 | 2014-03-19 | 詹森药业有限公司 | Ccr2的哌啶基丙烯酰胺拮抗剂 |
| US20110207784A1 (en) | 2008-08-14 | 2011-08-25 | The United States Of America, As Represented By The Secretary, | Oxadiazole-2-oxides as antischistosomal agents |
| JP2010254629A (ja) | 2009-04-27 | 2010-11-11 | Bayer Cropscience Ag | 光学活性アゾリン誘導体 |
| TW201109327A (en) | 2009-05-28 | 2011-03-16 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| CA2767474A1 (en) | 2009-07-10 | 2011-01-13 | Vivalis | Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use |
| RU2417082C2 (ru) | 2009-07-14 | 2011-04-27 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения |
| EP2513268B1 (en) | 2009-12-17 | 2019-02-20 | The Lubrizol Corporation | Use of an aromatic compound as antiwear agent in lubricants |
| NZ601629A (en) | 2010-01-27 | 2014-11-28 | Pharma Ltd Ab | Polyheterocyclic compounds highly potent as hcv inhibitors |
| CN101851218B (zh) | 2010-04-27 | 2014-10-15 | 沈阳药科大学 | 4,5-二取代芳基异硒唑类衍生物及其用途 |
| EP2580215A4 (en) | 2010-06-10 | 2014-01-15 | Afraxis Holdings Inc | 8- (HETEROCYCYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| CA2801182A1 (en) | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
| WO2012013725A1 (en) | 2010-07-28 | 2012-02-02 | Medizinische Universität Wien | Vinylogous chalcone derivatives and their medical use |
| US9132136B2 (en) | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| TW201225957A (en) | 2010-09-17 | 2012-07-01 | Taisho Pharmaceutical Co Ltd | Glycine transporter inhibitor |
| WO2012045196A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Phosphoglycerate kinase inhibitors |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| WO2013025484A1 (en) | 2011-08-12 | 2013-02-21 | Lapchak Paul A | Polyphenol analogs to treat ischemia |
| US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2013065835A1 (ja) | 2011-11-04 | 2013-05-10 | 味の素株式会社 | 糖尿病治療用医薬組成物 |
| AU2013216721B2 (en) | 2012-02-10 | 2017-09-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9475783B2 (en) | 2012-03-21 | 2016-10-25 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
| RU2509770C2 (ru) | 2012-06-22 | 2014-03-20 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |
| RU2015111206A (ru) | 2012-08-30 | 2016-10-20 | Ниппон Синяку Ко., Лтд. | Пиридиновое производное и лекарственное средство |
| EP2909214B1 (en) | 2012-10-22 | 2020-07-22 | City of Hope | Etp derivatives |
| KR20150127249A (ko) | 2013-03-13 | 2015-11-16 | 보스톤 바이오메디칼, 인크. | 암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체 |
| US20160108031A1 (en) | 2013-04-30 | 2016-04-21 | Heinrich-Heine-Universitat Dusseldorf | Inhibitors of nhr2 and/or runx1/eto-tetramerization |
| KR20150027922A (ko) | 2013-09-04 | 2015-03-13 | 주식회사 대웅제약 | 신규한 항진균성 피리디닐하이드라자이드 유도체 |
| CN105518014B (zh) | 2013-09-09 | 2018-03-23 | 上海研健新药研发有限公司 | C‑芳基葡糖苷衍生物、其制备方法及其在医药上的应用 |
| WO2015069110A1 (en) | 2013-11-07 | 2015-05-14 | Aapa B.V. | Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders |
| EP3121175B1 (en) * | 2014-03-17 | 2019-12-04 | Daiichi Sankyo Company, Limited | 1,3-benzodioxole derivatives as ezh1 and/or ezh2 inhibitors |
| MY185765A (en) | 2014-06-17 | 2021-06-06 | Pfizer | Substituted dihydroisoquinolinone compounds |
| CA2960757C (en) | 2014-09-11 | 2022-09-06 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
| WO2016130396A1 (en) * | 2015-02-13 | 2016-08-18 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN107847497B (zh) | 2015-07-30 | 2021-03-30 | 第一三共株式会社 | 用于成人t细胞白血病/淋巴瘤的治疗和/或预防剂 |
| AU2016357900B2 (en) | 2015-11-19 | 2020-09-17 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofuran derivative, preparation method thereof and use thereof in medicine |
| DK3402784T3 (da) | 2016-01-13 | 2020-05-25 | Gruenenthal Gmbh | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater |
| MX2018009633A (es) | 2016-02-09 | 2018-12-17 | Inventisbio Inc | Inhibidor de indoleamina-2,3-dioxigenasa (ido). |
| US20170355708A1 (en) * | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| CN106727549A (zh) | 2016-11-26 | 2017-05-31 | 李�荣 | 一种治疗抑郁症的药物 |
| WO2018135556A1 (ja) | 2017-01-19 | 2018-07-26 | 第一三共株式会社 | Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物 |
| WO2018170513A1 (en) | 2017-03-17 | 2018-09-20 | Cornell University | Compounds and compositions for inhibition and elimination of zika infection and uses for same |
| CA3063440A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
| EP3700527A4 (en) | 2017-10-25 | 2021-03-10 | Children's Medical Center Corporation | PAPD5 INHIBITORS AND METHOD OF USING THEM |
| GB201718285D0 (en) | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| JP2021035913A (ja) | 2017-12-21 | 2021-03-04 | 石原産業株式会社 | Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤 |
| EP3737362A1 (en) | 2018-01-12 | 2020-11-18 | Kdac Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| JP2019168611A (ja) | 2018-03-23 | 2019-10-03 | 株式会社Adeka | 光学フィルタ |
| US20210093591A1 (en) | 2018-03-30 | 2021-04-01 | San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation | Methods for mitigating and preventing proteostasis-based injuries |
| SG11202009438UA (en) | 2018-04-18 | 2020-11-27 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
-
2019
- 2019-04-17 SG SG11202009438UA patent/SG11202009438UA/en unknown
- 2019-04-17 MX MX2020010999A patent/MX2020010999A/es unknown
- 2019-04-17 AU AU2019255310A patent/AU2019255310B2/en active Active
- 2019-04-17 LT LTEPPCT/US2019/027932T patent/LT3781561T/lt unknown
- 2019-04-17 CR CR20200553A patent/CR20200553A/es unknown
- 2019-04-17 PT PT197223639T patent/PT3781561T/pt unknown
- 2019-04-17 BR BR112020021194-0A patent/BR112020021194A2/pt unknown
- 2019-04-17 CN CN201980026504.1A patent/CN111989325B/zh active Active
- 2019-04-17 PE PE2020001613A patent/PE20201448A1/es unknown
- 2019-04-17 MD MDE20210170T patent/MD3781561T2/ro unknown
- 2019-04-17 TW TW108113388A patent/TWI828677B/zh active
- 2019-04-17 UA UAA202006100A patent/UA127357C2/uk unknown
- 2019-04-17 SI SI201930767T patent/SI3781561T1/sl unknown
- 2019-04-17 JP JP2020557175A patent/JP7256823B2/ja active Active
- 2019-04-17 ES ES19722363T patent/ES2983344T3/es active Active
- 2019-04-17 RS RS20240661A patent/RS65621B1/sr unknown
- 2019-04-17 DK DK19722363.9T patent/DK3781561T3/da active
- 2019-04-17 EP EP19722363.9A patent/EP3781561B1/en active Active
- 2019-04-17 WO PCT/US2019/027932 patent/WO2019204490A1/en active Application Filing
- 2019-04-17 CN CN202510130368.8A patent/CN119954787A/zh active Pending
- 2019-04-17 AR ARP190101038A patent/AR114793A1/es unknown
- 2019-04-17 EP EP24160308.3A patent/EP4421072A1/en active Pending
- 2019-04-17 HU HUE19722363A patent/HUE066783T2/hu unknown
- 2019-04-17 HR HRP20240793TT patent/HRP20240793T1/hr unknown
- 2019-04-17 FI FIEP19722363.9T patent/FI3781561T3/fi active
- 2019-04-17 IL IL278013A patent/IL278013B2/en unknown
- 2019-04-17 SM SM20240233T patent/SMT202400233T1/it unknown
- 2019-04-17 KR KR1020207032832A patent/KR102798145B1/ko active Active
- 2019-04-17 EA EA202092490A patent/EA202092490A1/ru unknown
- 2019-04-17 MA MA52288A patent/MA52288B1/fr unknown
- 2019-04-17 PL PL19722363.9T patent/PL3781561T3/pl unknown
- 2019-04-17 KR KR1020257012107A patent/KR20250073166A/ko active Pending
- 2019-04-17 CA CA3098428A patent/CA3098428A1/en active Pending
- 2019-04-18 US US16/387,851 patent/US10689371B2/en active Active
-
2020
- 2020-04-23 US US16/856,454 patent/US11274095B2/en active Active
- 2020-09-25 PH PH12020551578A patent/PH12020551578A1/en unknown
- 2020-10-16 CL CL2020002698A patent/CL2020002698A1/es unknown
- 2020-11-17 CO CONC2020/0014217A patent/CO2020014217A2/es unknown
-
2023
- 2023-03-31 JP JP2023057753A patent/JP2023082132A/ja active Pending
- 2023-04-28 US US18/140,730 patent/US20240116905A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240793T1 (hr) | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba | |
| PH12017502246A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| MA35903B1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MX390793B (es) | Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio. | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| JO3430B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| SA518392049B1 (ar) | مشتقات أمونيوم جديدة، عملية لتحضيرها وتركيبات صيدلانية تحتوي عليها | |
| AR082201A1 (es) | Bencenosulfonamidas utiles como inhibidores del canal de sodio | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| JP2013531031A5 (hr) | ||
| PH12017502314A1 (en) | New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12014500919A1 (en) | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | |
| JP2016506960A5 (hr) | ||
| ME02452B (me) | Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti | |
| JO3160B1 (ar) | مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها | |
| MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| JO3275B1 (ar) | مشتقات بيرول جديدة وطريقة لتحضيرها وتركيبات صيدلانية التي تحتوي عليها | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| GEP20207177B (en) | Pyridone amides as modulators of sodium channels | |
| MX2016007125A (es) | Una composicion de revestimiento. | |
| MX375556B (es) | Compuestos de benzoxaborol tricíclicos y usos de los mismos. | |
| AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
| HRP20191826T4 (hr) | Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta | |
| PH12013500041A1 (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof |